文献速递银屑病与炎症性皮肤病

艾克司单抗治疗中重度斑块状银屑病患者的长期安全性特征:来自11项临床试验的整合分析

Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2018-11-22

该整合分析汇集11项临床试验中5689例接受艾克司单抗治疗的中重度斑块状银屑病患者,累计暴露12061.5患者年。超过156周内83.9%患者报告治疗中出现的不良事件,严重不良事件报告率为11.8%,死亡0.4%(n=23)。结论认为3年长期维持治疗未显示新的安全性信号。

要点

  • 5689例患者累计艾克司单抗暴露12061.5患者年,多数机会性感染为黏膜皮肤念珠菌病。
  • 口服念珠菌感染暴露调整发生率(95%CI)为0.9(0.8,1.1)/100患者年。
  • 严重不良事件报告率11.8%,死亡0.4%(n=23),未观察到特殊关注不良事件发生率上升趋势。

核心结论

  • 中重度斑块状银屑病患者接受艾克司单抗3年长期维持治疗未显示新的安全性信号。

研究设计与样本

  • 整合11项临床试验的安全性数据,分析12周诱导期、12至60周维持期及所有接受艾克司单抗治疗的患者,报告每100患者年的暴露调整发生率。

主要发现

  • 共5689例患者,艾克司单抗累计暴露12061.5患者年。
  • 超过156周内,83.9%(n=4775)的患者报告治疗中出现的不良事件。
  • 机会性感染发生率(95%CI)为1.8(1.6,2.1)/100患者年,多数为黏膜皮肤念珠菌病;口服念珠菌感染发生率为0.9(0.8,1.1)/100患者年。
  • 特殊关注不良事件的发生率未呈现上升趋势。
  • 严重不良事件报告率为11.8%,死亡发生于0.4%(n=23)的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psoriasis in many patients is a chronic and recalcitrant disease that requires long-term treatment, reinforcing the importance of long-term safety data. Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A, is approved for treating patients with moderate-to-severe plaque psoriasis. OBJECTIVE: To determine long-term safety of ixekizumab in psoriasis. METHODS: Integrated safety data are presented from 12-week induction period, 12-60-week maintenance period, and from all ixekizumab-treated patients from 11 clinical studies. Exposure-adjusted incidence rates (IRs) per 100 patient-years are reported. RESULTS: Overall, 5689 patients accounted for 12 061.5 patient-years of ixekizumab exposure from 11 studies. Over 156 weeks, a total of 83.9% (n = 4775) of patients reported treatment-emergent adverse events (AEs). Most opportunistic infections (IR [95% confidence interval; CI] 1.8 [1.6, 2.1]) reported were mucocutaneous candidiasis. The IR (95% CI) for oral Candida infection was 0.9 (0.8, 1.1). There was no trend of increase in IR of AEs of special interest. Serious AEs were reported in 11.8% of patients; death occurred in 0.4% (n = 23) of patients. CONCLUSION: The 3-year, long-term maintenance treatment with ixekizumab did not show any new safety signals in patients with moderate-to-severe plaque psoriasis.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Langley RG, Kimball AB, Nak H, et al. Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials. J Eur Acad Dermatol Venereol. 2018. PMID: 30198588. doi:10.1111/jdv.15242

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。